Linked Life Data

8312279

Source:http://linkedlifedata.com/resource/pubmed/id/8312279

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8312279rdf:typepubmed:Citationlld:pubmed
pubmed-article:8312279lifeskim:mentionsumls-concept:C0205147lld:lifeskim
pubmed-article:8312279lifeskim:mentionsumls-concept:C0015491lld:lifeskim
pubmed-article:8312279lifeskim:mentionsumls-concept:C0033618lld:lifeskim
pubmed-article:8312279lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:8312279lifeskim:mentionsumls-concept:C0220905lld:lifeskim
pubmed-article:8312279lifeskim:mentionsumls-concept:C1552302lld:lifeskim
pubmed-article:8312279lifeskim:mentionsumls-concept:C1552291lld:lifeskim
pubmed-article:8312279lifeskim:mentionsumls-concept:C0441712lld:lifeskim
pubmed-article:8312279pubmed:issue6lld:pubmed
pubmed-article:8312279pubmed:dateCreated1994-3-22lld:pubmed
pubmed-article:8312279pubmed:abstractTextHemophilia B-Leyden is characterized by the gradual amelioration of bleeding after the onset of puberty. All Leyden phenotype mutations found to date lie within the Leyden-specific region, which spans roughly nt-40 to +20 in the 5' end of the human factor IX gene. With HepG2 cell nuclear extracts, the Leyden-specific region and its immediate neighboring region of the normal factor IX gene showed five DNase I footprints: FP-I (nt +4 to +19), FP-II (nt -16 to -3), FP-III (nt -27 to -19), FP-IV (nt -67 to -49), and FP-V (nt -99 to -77). Protein binding affinities of short oligonucleotides containing sequences of FP-I, FP-II, or FP-III were substantially reduced in the presence of Leyden phenotype mutations in these areas, correlating well with the negative effects of these mutations on factor IX gene expression. A Leyden phenotype mutation at nt -20 (T to A) caused a loss of both footprints FP-III and FP-II but generated a new footprint, FP-III' (nt -34 to -23), partially overlapping with FP-III, indicating mutation-dependent competitive protein binding at these sites. Although the FP-III' area contains an androgen responsive element-like sequence, the nuclear protein that binds at FP-III' is not androgen receptor. The protein was not recognized by anti-androgen receptor antibody and, furthermore, was present not only in liver but also in both androgen receptor-positive and androgen receptor-negative cells in electrophoretic mobility shift assays. The nuclear concentration of this protein increased significantly upon treatment of the HepG2 cells with testosterone. Its binding affinity to an oligonucleotide (-32sub) containing the FP-III' sequence was greatly reduced in the presence of exogenous androgen receptor, suggesting a possible interaction of this protein with androgen receptor. The affinities of both this protein and a protein which binds to FP-III (presumably HNF-4) to -32sub with a mutation at nt -26 were grossly lowered. These findings suggest that the amelioration of hemophilia B-Leyden with a mutation at nt -20 after puberty involves binding of a specific non-androgen receptor nuclear protein at FP-III' and it is able to substitute for the function of a protein bound at FP-III in the normal gene optimally through its elevated interaction with androgen receptor upon a surge of testosterone.(ABSTRACT TRUNCATED AT 400 WORDS)lld:pubmed
pubmed-article:8312279pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8312279pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8312279pubmed:languageenglld:pubmed
pubmed-article:8312279pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8312279pubmed:citationSubsetIMlld:pubmed
pubmed-article:8312279pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8312279pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8312279pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8312279pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8312279pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8312279pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8312279pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8312279pubmed:statusMEDLINElld:pubmed
pubmed-article:8312279pubmed:monthFeblld:pubmed
pubmed-article:8312279pubmed:issn0006-2960lld:pubmed
pubmed-article:8312279pubmed:authorpubmed-author:FrenchF SFSlld:pubmed
pubmed-article:8312279pubmed:authorpubmed-author:SalierJ PJPlld:pubmed
pubmed-article:8312279pubmed:authorpubmed-author:KurachiKKlld:pubmed
pubmed-article:8312279pubmed:authorpubmed-author:KurachiSSlld:pubmed
pubmed-article:8312279pubmed:authorpubmed-author:WuC TCTlld:pubmed
pubmed-article:8312279pubmed:authorpubmed-author:FurukawaMMlld:pubmed
pubmed-article:8312279pubmed:authorpubmed-author:WilsonE JEJlld:pubmed
pubmed-article:8312279pubmed:issnTypePrintlld:pubmed
pubmed-article:8312279pubmed:day15lld:pubmed
pubmed-article:8312279pubmed:volume33lld:pubmed
pubmed-article:8312279pubmed:ownerNLMlld:pubmed
pubmed-article:8312279pubmed:authorsCompleteYlld:pubmed
pubmed-article:8312279pubmed:pagination1580-91lld:pubmed
pubmed-article:8312279pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:meshHeadingpubmed-meshheading:8312279-...lld:pubmed
pubmed-article:8312279pubmed:year1994lld:pubmed
pubmed-article:8312279pubmed:articleTitleRegulatory mechanism of human factor IX gene: protein binding at the Leyden-specific region.lld:pubmed
pubmed-article:8312279pubmed:affiliationDepartment of Human Genetics, University of Michigan Medical Center, Ann Arbor 48109-0618.lld:pubmed
pubmed-article:8312279pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8312279pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8312279lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8312279lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8312279lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8312279lld:pubmed